Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

The trial aims to compare the efficacy and safety of the therapy as a single agent with tenofovir disoproxil fumarate.

Q2 2025 Management View Jennifer S. Buell, President and CEO, stated that MiNK continues to be "the most clinically advanced company, industrializing off-the-shelf, invariant natural killer T cells." ...

Quantum signed a manufacturing agreement for the production of Lucid-MS as it prepares for a Phase 2 trial of the ...

Kansas athletic director Travis Goff explained how David Booth’s donation gives the Jayhawks more confidence for phase two of ...

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

Despite the outcome, VE202 was well tolerated. Most adverse events were mild or moderate, with no reports of treatment-related serious adverse events. Further analyses on bacterial colonisation and ...

Neuropathic corneal pain was significantly reduced after 12 weeks of treatment with urcosimod in a phase 2 trial, according ...

A fascinating look back at the potential 'Star Trek' sequel TV show includes some incredible imaginings of what the new USS ...

Phase 2 of the Wuthering Waves 2.5 update was released on August 14, 2025, bringing in the second set of events and banners ...

The city of Pflugerville is nearing completion of the most recent phase of the Kelly Lane expansion, following the completion ...